Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments

• Published in: bioRxiv
• Main Authors: Delamarre, Adele, Decraecker, Marie, Blanc, Jean-Frederic, Di-Tommaso, Sylvaine, Dourthe, Cyril, Jean-William Dupuy, Moreau, Melanie, Allain, Nathalie, Mahouche, Isabelle, Giraud, Julie, Benard, Giovanni, Lalou, Claude, Pinson, Benoit, Bioulac-Sage, Paulette, Toulouse, Caroline, Morisset, Audrey, Boursier, Jerome, Brigitte Le Bail, Anne-Aurelie Raymond, Saltel, Frederic
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 04.01.2025; Cold Spring Harbor Laboratory
• Edition: 1.1
• Subjects: Bevacizumab; Biopsy; Cancer Biology; Hepatocellular carcinoma; Immunotherapy; Liver cancer; Mass spectroscopy; Proteomes; Proteomics; Response rates; Tumors

Purpose: Hepatocellular carcinoma (HCC) is the most common form of liver cancer with a bad prognosis in case of advanced HCC, only eligible for palliative systemic therapies. After a decade of exclusive sorafenib monotherapy, with a response rate of <10%, the advent of immunotherapies represents...